Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind equivalence study of Loceryl versus generic amorolfine for onychomycosis without matrix involvement
2008-002427-90Phase 3Active
- Sponsor
- SUBSTIPHARM Développement
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of amorolfine in onychomycosis (2 arms), sponsored by SUBSTIPHARM Développement. Primary endpoint: Clinical and mycological efficacy. Started Jul 2008; status: active.
02
Drugs
amorolfine
03
Conditions
onychomycosis
Beyond the preview
Go deeper on 2008-002427-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002427-90.